Oncology & Cancer

Two therapeutic targets identified for deadly lung cancer

The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive ...

Oncology & Cancer

Unlocking therapies for hard-to-treat lung cancers

Now, a new Salk Institute study, published on July 24, 2019, in the journal Science Advances, shows that researchers could target these hard-to-treat cancers by pursuing drugs that keep a cellular "switch," called CREB, from ...

Medical research

Targeting old bottleneck reveals new anticancer drug strategy

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists at Winship Cancer Institute of Emory University have identified a way of targeting ribonucleotide reductase that may avoid the toxicity ...

Oncology & Cancer

Uridine diphosphate glucose found to dampen lung cancer metastasis

In a study published online in Nature on June 26, research teams led by Dr. Yang Weiwei at the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (CAS) and Dr. Li Guohui from the Dalian Institute ...

Medications

Origin of resistance to lung-cancer drug discovered

Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...

page 1 from 15